MediPharm Labs Corp (MLZ.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
As of 08:05AM CEST. Market open.
| Previous close | 0.0410 |
| Open | 0.0460 |
| Bid | 0.0460 x 0 |
| Ask | 0.0616 x 0 |
| Day's range | 0.0460 - 0.0460 |
| 52-week range | 0.0269 - 0.0716 |
| Volume | |
| Avg. volume | 959 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 27 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.MediPharm Labs Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
MediPharm Labs ( TSE:LABS ) Full Year 2023 Results Key Financial Results Revenue: CA$33.1m (up 50% from FY 2022). Net...
PR NewswireMediPharm Labs Provides Conference Call Recording Details
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, has released and hosted a conference call regarding its full year and fourth quarter financial results for the period ended December 31, 2023.
PR NewswireMediPharm Labs Reports Fourth Quarter and Full Year Results
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended December 31, 2023.
© 2024 Yahoo. All rights reserved.